Oramed Pharmaceuticals Slated for Russell Index Inclusion
Oramed Pharmaceuticals is set to join the Russell 2000 and Russell 3000 indexes following the conclusion of the 2026 semi-annual reconstitution. The shift, which tracks the 4,000 largest U.S. stocks by market capitalization, will take effect at the market open on Monday, June 29, 2026.
The transition for the Nasdaq-listed firm occurs after the close of U.S. markets on Friday, June 26. FTSE Russell determines membership through objective, market-capitalization rankings and style attributes, capturing data as of April 30, 2026. Inclusion in the Russell 3000 Index provides a gateway for companies to be categorized into large-cap or small-cap benchmarks, influencing how institutional investors allocate capital across their portfolios.
Investment managers rely heavily on these indexes to track performance and manage index-based funds. With approximately $12.2 trillion in assets currently benchmarked against the Russell U.S. indexes, the addition marks a shift in Oramed’s market standing within the broader investment landscape.
Comments (0)
No comments yet. Be the first!